Topiramate
Product Images NDC 70934-772

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (70934 772 60 Master Bottle Label Approval Rev A 06 20)

Label (70934 772 60 Master Bottle Label Approval Rev A 06 20)
Topiramate Tablets USP 25 mg label from Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label states 60 tablets, prescription only, with storage instructions at 20°-25°C. It includes warnings to keep out of reach of children, store in original container, and protect from moisture. The label also references dosage instructions and contains a barcode and lot information.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of the active ingredient Topiramate as shown in the image. The diagram depicts the molecule's key atoms and bonds, including oxygen, sulfur, nitrogen, and carbon atoms arranged in a cyclic formation with attached functional groups.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A cumulative incidence curve showing time to first seizure for two Topiramate dosage groups: 50 mg/day (solid line) and 400 mg/day (dotted line). The vertical axis represents cumulative rates, the horizontal axis represents time in days, with data points extending to 500 days. A statistical p-value of 0.0002 is noted for comparison between groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
Bar chart showing the change from baseline to double-blind phase in average monthly migraine period rate for Topiramate at 50 mg/day, 100 mg/day, and 200 mg/day doses compared to placebo. Results from two studies (Study 10 and Study 11) are presented with standard error bars. Statistical significance is indicated at p<0.010 and p<0.001 levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.